Evidence map›Paper›PMID 34006921›Full record

ArticleScientific reports2021

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.

Lindsay T Fourman, Takara L Stanley, James M Billingsley, Shannan J Ho Sui, Meghan N Feldpausch, Autumn Boutin, Isabel Zheng, Colin M McClure, Kathleen E Corey, Martin Torriani and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism · 2022 · on this map
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Lindsay T Fourman *Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street 5LON207, Boston, MA, 02114, USA.
Takara L Stanley *Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street 5LON207, Boston, MA, 02114, USA.
James M BillingsleyHarvard Chan Bioinformatics Core, Department of Biostatistics, Harvard School of Public Health, Boston, MA, 02115, USA.
Shannan J Ho SuiHarvard Chan Bioinformatics Core, Department of Biostatistics, Harvard School of Public Health, Boston, MA, 02115, USA.
Meghan N FeldpauschMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street 5LON207, Boston, MA, 02114, USA.
Autumn BoutinMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street 5LON207, Boston, MA, 02114, USA.
Isabel ZhengMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street 5LON207, Boston, MA, 02114, USA.
Colin M McClureMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street 5LON207, Boston, MA, 02114, USA.
Kathleen E CoreyLiver Center, Gastroenterology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Martin TorrianiDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
David E KleinerLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA.
Colleen M HadiganNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Raymond T ChungLiver Center, Gastroenterology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Steven K GrinspoonMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street 5LON207, Boston, MA, 02114, USA. sgrinspoon@mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · USNational Cancer Institute · USNational Institute of Allergy and Infectious Diseases · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GEORG Michael LAUER · 2009 to 2026
$48.1M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M
Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
HIV, HCV, Hippo, and Liver Disease ProgressionR01AI136715 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2018 to 2022
$3.4M
Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative U01 GrantU01AI115711 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GRINSPOON, STEVEN K., HADIGAN, COLLEEN M · 2015 to 2017
$2.0M
HIV-Associated Macrophage Alterations and Progressive Liver DiseaseR01DK108370 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2015 to 2019
$1.6M
In Utero HIV Exposure and Metabolic Disease Risk in HIV-Uninfected Young AdultsK23HD100266 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI FOURMAN, LINDSAY TARA · 2020 to 2024
$851k
NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI136715NIAID NIH HHS U01 AI115711NIAID NIH HHS U19 AI082630NICHD NIH HHS K23 HD100266NIDDK NIH HHS P30 DK040561NIDDK NIH HHS R01 DK108370NIH HHS P30AI060354NIH HHS P30DK040561NIH HHS R01DK108370NIH HHS U01AI115711
6 · The paper itself

Abstract

NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population. Tesamorelin has been demonstrated to reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD. We further showed that tesamorelin downregulated hepatic gene sets involved in inflammation, tissue repair, and cell division. Nonetheless, effects of tesamorelin on individual plasma proteins pertaining to these pathways are not known. Leveraging our prior randomized-controlled trial and transcriptomic approach, we performed a focused assessment of 9 plasma proteins corresponding to top leading edge genes within differentially modulated gene sets. Tesamorelin led to significant reductions in vascular endothelial growth factor A (VEGFA, log

Indexed as

TranscriptomeAdolescentAdultAgedBlood ProteinsDouble-Blind MethodFemaleGrowth Hormone-Releasing HormoneGrowth SubstancesHIV InfectionsHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePlacebosProteomicsBlood ProteinsGrowth Hormone-Releasing HormoneGrowth SubstancesPlacebostesamorelinTransforming Growth Factor beta1Vascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID34006921
PMCPMC8131688
OpenAlexW3160832982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.